| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,524 |
Challenger neutralises Dividend Reinvestment Plan
|
28 Feb 2025 9:48AM |
$5.950 |
$7.990 |
risen by
34.29%
|
|
| Motorcycle Holdings Limited (MTO) ORDINARY FULLY PAID |
Consumer Discretionary |
$176 |
Director Resignation
|
28 Feb 2025 9:48AM |
$1.980 |
$2.380 |
risen by
20.20%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$364 |
Dividend/Distribution - KSL
|
28 Feb 2025 9:48AM |
$1.170 |
$1.260 |
risen by
7.69%
|
|
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,524 |
Update - Dividend/Distribution - CGF
|
28 Feb 2025 9:47AM |
$5.950 |
$7.990 |
risen by
34.29%
|
|
| Pier 12 Capital Limited (AVC) ORDINARY FULLY PAID |
Financials |
$44 |
AVC Voluntary Delisting from ASX
|
28 Feb 2025 9:47AM |
$0.615 |
$0.500 |
fallen by
18.70%
|
|
AVC - Price-sensitive ASX Announcement
Full Release
Key Points
- AVC submitted a formal request for delisting on 25 February 2025.
- ASX approved the delisting on 27 February 2025.
- Expected delisting date is 8 May 2025.
- Reasons for delisting include small market capitalization and limited trading liquidity.
- Delisting aims to reduce costs associated with ASX listing.
- Shareholders are advised to sell their shares before 6 May 2025.
- An on-market buyback of shares is proposed, pending shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Delorean Corporation Limited (DEL) ORDINARY FULLY PAID |
Utilities |
$35 |
1H FY2025 Investor Update Presentation
|
28 Feb 2025 9:47AM |
$0.125 |
$0.160 |
risen by
28%
|
|
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$18 |
Issue of Converting Notes
|
28 Feb 2025 9:47AM |
$0.030 |
$0.055 |
risen by
83.33%
|
|
HCT - Price-sensitive ASX Announcement
Full Release
Key Points
- Holista Colltech Limited announces the issuance of converting notes.
- Total raising of approximately AUD1,545,100.
- Funds to enhance working capital and repay ASIC obligations.
- Converting notes feature a maturity date of June 30, 2025.
- Conversion price set at AUD 0.0315 per share.
- Investors include Mr. Greg Pilant and Mr. Tee Kian Heng.
- Mr. Pilant will join the board for a nominal fee.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$569 |
Change of Director's Interest Notice - S. Washer
|
28 Feb 2025 9:47AM |
$0.455 |
$0.290 |
fallen by
36.26%
|
|
| Vital Metals Limited (VML) ORDINARY FULLY PAID |
Materials |
$6 |
Vital Expands Tardiff Scoping Study to Include Niobium
|
28 Feb 2025 9:47AM |
$0.002 |
$0.001 |
fallen by
33.33%
|
|
VML - Price-sensitive ASX Announcement
Full Release
Key Points
- Vital expands Tardiff Scoping Study to include niobium recovery.
- Niobium hosted in the same geological formations as rare earth minerals.
- Tardiff estimated to contain 636,000 tonnes of NdPr and 578,000 tonnes of Nb2O5.
- Initial metallurgical testwork showed a 15% recovery rate for niobium.
- Additional testwork will take approximately 8 weeks.
- Vital is working with the Canadian Government to establish a rare earths processing hub.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$536 |
Response to ASX Aware Letter
|
28 Feb 2025 9:46AM |
$3.270 |
$2.730 |
fallen by
16.51%
|
|
ACL - Price-sensitive ASX Announcement
Full Release
Key Points
- ACL issued guidance for FY25 revenue of $725M - $752M and underlying EBIT of $65M - $73M.
- ACL reaffirmed its guidance on multiple occasions including on 26 February 2025.
- All sell-side analysts' forecasts were within ACL's guidance range.
- ACL believes the release of its half-year reports will not materially affect its securities' price.
- ACL confirmed compliance with Listing Rules and has authorized the response to ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Joyce Corporation Limited (JYC) ORDINARY FULLY PAID |
Consumer Discretionary |
$135 |
Dividend/Distribution - JYC
|
28 Feb 2025 9:46AM |
$4.580 |
$4.560 |
fallen by
0.44%
|
|
| Life360 Inc (360) CDI 3:1 FOREIGN EXEMPT XNGS |
Information Technology |
$5,267 |
SEC Form 10-K
|
28 Feb 2025 9:46AM |
$21.740 |
$31.400 |
risen by
44.43%
|
|
| Gorilla Gold Mines Ltd (GG8) ORDINARY FULLY PAID |
Materials |
$254 |
Lakeview High-Grade Intercepts Grow Mineralisation
|
28 Feb 2025 9:45AM |
$0.255 |
$0.405 |
risen by
58.82%
|
|
GG8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Lakeview Prospect's mineralization extended to 400m strike length.
- Best gold intercepts include 19m @ 18.1 g/t Au and 11m @ 24.8 g/t Au.
- Lakeview is located 97km north of Kalgoorlie WA.
- Ongoing drilling at Lakeview and Mulwarrie.
- Lakeview gold mineralization associated with major fault and ultramafic rocks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$10 |
1HFY25 Results Announcement
|
28 Feb 2025 9:45AM |
$0.135 |
$0.095 |
fallen by
29.63%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong Sales Growth: US sales increased by approximately 100% in 2024 compared to 2023.
- Revenue for 1H FY25 reached A$102,000, a 167% increase from the prior corresponding period.
- Global Expansion: New distribution agreements secured with Accession Medical Supplies and Union MediScience B.S.C.
- Clinical Advancements: The NervAlign® Nerve Guide Matrix showed positive animal study results.
- Successful IPO: Raised $7 million and listed on the ASX on 26 November 2024.
- Surgeon Feedback: Positive reception highlights the NervAlign® Nerve Cuff’s benefits.
- Strong Cash Position: Maintained a cash balance of $6.4 million as of 31 December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$4 |
Appendix 4D and Half Yearly Report
|
28 Feb 2025 9:45AM |
$0.020 |
$0.014 |
fallen by
30%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited generated revenues of $5,597,012 for the half-year ending December 31, 2024.
- The company reported a loss of $635,660, showing improvement from the previous year's larger loss.
- Operating costs decreased significantly due to cost reduction initiatives.
- Hydrix Services reported its strongest calendar year of sales in the last 5 years.
- The company has a cash position of $1,117,925 as of December 31, 2024.
- 61% of revenue came from international clients.
- The company is focused on driving cash operating profit through sales conversions and higher margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$10 |
1HFY25 Appendix 4D and Half Year Report
|
28 Feb 2025 9:44AM |
$0.135 |
$0.095 |
fallen by
29.63%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- ReNerve Limited reported a comprehensive loss of $1,843,656 for the half-year ending 31 December 2024.
- The loss increased by 29.8% compared to the previous year.
- The company raised $7 million through an IPO, and shares were listed on the ASX on 26 November 2024.
- US sales increased by around 100% compared to the previous year.
- Partnerships were formed with Accession Medical Supplies in Hong Kong and Mediscience B.S.C. in Bahrain to expand market reach.
- ReNerve is developing the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix with positive clinical outcomes.
- No dividends were declared during the reporting period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$569 |
Notification of cessation of securities - BOT
|
28 Feb 2025 9:44AM |
$0.455 |
$0.290 |
fallen by
36.26%
|
|
| Blackwall Limited (BWF) ORDINARY FULLY PAID |
Financials |
$61 |
Additional Dividend/Distribution - BWF
|
28 Feb 2025 9:44AM |
$0.410 |
$0.365 |
fallen by
10.98%
|
|
BWF - Price-sensitive ASX Announcement
Full Release
Key Points
- New announcement by Blackwall Limited regarding dividend distribution
- Total dividend distribution amount per security is AUD 0.025
- The dividend is fully franked
- Payment date is set for 08/04/2025
- Record date is 11/03/2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carindale Property Trust (CDP) ORDINARY UNITS FULLY PAID |
Real Estate |
$410 |
Application for quotation of securities - CDP
|
28 Feb 2025 9:44AM |
$4.710 |
$4.950 |
risen by
5.10%
|
|
| Freelancer Limited (FLN) ORDINARY FULLY PAID |
Industrials |
$90 |
Appendix 3Y
|
28 Feb 2025 9:43AM |
$0.165 |
$0.200 |
risen by
21.21%
|
|
| Ora Banda Mining Ltd (OBM) ORDINARY FULLY PAID |
Materials |
$1,564 |
Sand King Update
|
28 Feb 2025 9:43AM |
$0.925 |
$0.830 |
fallen by
10.27%
|
|
OBM - Price-sensitive ASX Announcement
Full Release
Key Points
- First Sand King Underground development ore processed through the Davyhurst plant with a reconciled grade 4.3% above expectations.
- Metallurgical recovery reconciled at 88.2%, which is 1.2% above the expected 87%.
- Early grade control drilling indicates a 19% uplift in gold ounce endowment thus far.
- Identification of at least three 'blow-out' zones in grade control drilling supports potential for bulk stoping opportunities.
- Capital projects now completed with commissioning of primary fan and escapeway in February.
- Sand King Underground remains on track to reach its steady state production rate in June.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$569 |
Application for quotation of securities - BOT
|
28 Feb 2025 9:43AM |
$0.455 |
$0.290 |
fallen by
36.26%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$364 |
FY24 Appendix 4E Preliminary Final Report
|
28 Feb 2025 9:42AM |
$1.170 |
$1.260 |
risen by
7.69%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax of PGK 102.5 million for FY24.
- Underlying NPAT increased by 7% to PGK 111.9 million.
- Total revenue increased by 21% to PGK 488.8 million.
- Foreign exchange income surged 68% to PGK 86.2 million.
- Declared an unfranked final dividend of AUD 6.0 cents per share.
- Operating expenses rose by 31% to PGK 286.6 million.
- Capital adequacy ratio stands at 18.4%, above the required minimum.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aumake Limited (AUK) ORDINARY FULLY PAID |
Consumer Discretionary |
$6 |
Aumake Appoints Dr. Anthony Noble as Non-Executive Chairman
|
28 Feb 2025 9:42AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
| WEB Travel Group Limited (WEB) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,644 |
Notification of cessation of securities - WEB
|
28 Feb 2025 9:42AM |
$4.920 |
$4.550 |
fallen by
7.52%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
